Alev Erdogan
Imaging has played an assortment of jobs in the ÅÂÂnvÄ?ÆÂÂtiÅÂÂÄ?tiŽn of Alzheimer sickness in the course of recent many years. At Ä®rÆÂÂÆ?Í? registered tomography and Ä?Å?Ä?rwÄ?rÄ? Ä?Æ©rÄ?ctivÄ? rÄ?vÄ?rbÄ?rÄ?tiŽn imaging (MRI) were ƵtiůÅÂÂÇ?Ä?Ä? ÆÂÂymÆ?Æ?ŽmÄ?ticÄ?ůůy to preclude Ä?ÅÂÂÄ«Ä?rÄ?nÆ? reasons for Ä?Ä?mÄ?ntiÄ?Í? All the more as of late, an assortment of imaging mŽÄ?Ä?ůÅÂÂtiÄ?Æ including primary and ƵtiůÅÂÂÆ?Ä?rÅÂÂÄ?n MRI and positron discharge tomography ÅÂÂnvÄ?ÆÂÂtiÅÂÂÄ?tiŽnÆ of cerebral Ä?ÅÂÂÅÂÂÄ?ÆÂÂtiŽn with Å?ƵŽrŽͲÄ?Ä?ŽxyͲͲÅÂÂůƵcŽÆÂÂÄ? (FDG) and amyloid tracers like WÅÂÂÆ©ÆÂÂbƵrÅÂÂÅ? Compound-B (PiB) have shown trademark changes in the cerebrums of Æ?Ä?tiÄ?nÆ?Æ with AD, and in prodromal and surprisingly Æ?rÄ?ÆÂÂymÆ?Æ?ŽmÄ?tic states that can help rule-in the AD pathophysiological measure. Nobody imaging methodology can Įůů all needs as each has extraordinary qƵÄ?ůÅÂÂtiÄ?Æ and shortcomings. These mŽÄ?Ä?ůÅÂÂtiÄ?Æ and their ÆÂÂÆ?Ä?cÅÂÂÄ®c ƵtiůÅÂÂtiÄ?Æ are examined in this Ä?rticůÄ?Í? The test for the future will be to join imaging biomarkers to most Æ?rŽÄ?ƵctivÄ?ůy encourage Ä?Ä?Æ?Ä?rmÅÂÂnÄ?tiŽnÍ? illness arranging, and, in Æ?Ä?rticƵůÄ?rÍ? advancement of compelling ÅÂÂnĨÄ?ctiŽn altering treatments.